Genmab — Februar 2019
-
Fra Børsen - citat: Med den nuværende behandlingstid kan man behandle omkring to patienter om dagen per stol, men det vil ændre sig til fire per time inklusive en kop kaffe med den subkutane version. Og det vil, tror jeg, dramatisk booste brugen af Darzalex
-
Uanset, så hvade David en exellent pointe: "..and I think we saw in 2018, we didn't have any movement of our guidance overall. And of course, look, I've been very transparent with the milestones that are in there. They're binary. And look, for the long-term trajectory, our DARZALEX sales, whether they're 2.99 billion in 2019 or 3.01 billion in 2019 makes absolutely no difference of where the future success of DARZALEX will be.."!
-
Forventes SC versionen at være på markedet allerede i starten af 2020?
-
Artikel giver fint overblik... https://www.euroinvestor.dk/nyheder/2019/02/21/genmab-ceo-forbedret-udgave-af-darzalex-vil-loefte-salget-markant/13977376
-
Det står klokkeklart i Børsen i dag (citat fra JdW). Jeg har blot tidligere hørt starten af 2021, og spekulerede på om det var gået galt med et tal.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind